Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

168.01 +5.38 (+3.31%)
Streaming Delayed Price Updated: 10:33 AM EST, Dec 8, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 254,780
Open 163.23
Bid (Size) 168.00 (1)
Ask (Size) 168.21 (2)
Prev. Close 162.63
Today's Range 162.38 - 168.50
52wk Range 117.08 - 312.96
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From BioNTech SE
Via Globe NewsWire

Performance

YTD
-27.54%
-27.54%
1 Month
+4.53%
+4.53%
3 Month
+16.58%
+16.58%
6 Month
+3.88%
+3.88%
1 Year
-43.85%
-43.85%

More News

Read More
BioNTech, Ryvu Therapeutics Join Forces For Immuno-Modulatory Candidates
Via Benzinga
US Supports Delay On COVID Patent Waiver Extension Decision
Via Benzinga
UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids
Via Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Via Benzinga
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
From BioNTech SE
Via Globe NewsWire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Is Novavax Stock a Buy Now?
Via The Motley Fool
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Via Benzinga
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
Via Benzinga
Is Now the Time for Income Investors to Buy This Big Pharma Stock?
Via The Motley Fool
7 Stocks on the Perfect 10 List
Via InvestorPlace
PFE Stock Could Be the Booster Shot Your Portfolio Needs Now
Via InvestorPlace
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
Via Benzinga
2 Reasons to Buy Pfizer and 1 Reason to Sell
Via The Motley Fool
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Via Benzinga
7 Stocks to Sell Right Now… and 1 to Buy
Via InvestorPlace
Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages
Via Benzinga
Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review
Via Investor's Business Daily
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
From BioNTech SE
Via Globe NewsWire
Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?
Via Investor's Business Daily
Ukraine Asserts It Does Not Take Blame For Poland Missile Attack, Crypto Exchange Gemini Suffers $485M In Outflows, FTX, Bahamas Regulator Lock Horns Over Control Of Bankruptcy Proceedings: Top Stories Thursday, Nov. 17
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.